Literature DB >> 16467349

Regional and cellular gene expression changes in human Huntington's disease brain.

Angela Hodges1, Andrew D Strand, Aaron K Aragaki, Alexandre Kuhn, Thierry Sengstag, Gareth Hughes, Lyn A Elliston, Cathy Hartog, Darlene R Goldstein, Doris Thu, Zane R Hollingsworth, Francois Collin, Beth Synek, Peter A Holmans, Anne B Young, Nancy S Wexler, Mauro Delorenzi, Charles Kooperberg, Sarah J Augood, Richard L M Faull, James M Olson, Lesley Jones, Ruth Luthi-Carter.   

Abstract

Huntington's disease (HD) pathology is well understood at a histological level but a comprehensive molecular analysis of the effect of the disease in the human brain has not previously been available. To elucidate the molecular phenotype of HD on a genome-wide scale, we compared mRNA profiles from 44 human HD brains with those from 36 unaffected controls using microarray analysis. Four brain regions were analyzed: caudate nucleus, cerebellum, prefrontal association cortex [Brodmann's area 9 (BA9)] and motor cortex [Brodmann's area 4 (BA4)]. The greatest number and magnitude of differentially expressed mRNAs were detected in the caudate nucleus, followed by motor cortex, then cerebellum. Thus, the molecular phenotype of HD generally parallels established neuropathology. Surprisingly, no mRNA changes were detected in prefrontal association cortex, thereby revealing subtleties of pathology not previously disclosed by histological methods. To establish that the observed changes were not simply the result of cell loss, we examined mRNA levels in laser-capture microdissected neurons from Grade 1 HD caudate compared to control. These analyses confirmed changes in expression seen in tissue homogenates; we thus conclude that mRNA changes are not attributable to cell loss alone. These data from bona fide HD brains comprise an important reference for hypotheses related to HD and other neurodegenerative diseases.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16467349     DOI: 10.1093/hmg/ddl013

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  319 in total

1.  Striatal-enriched protein tyrosine phosphatase expression and activity in Huntington's disease: a STEP in the resistance to excitotoxicity.

Authors:  Ana Saavedra; Albert Giralt; Laura Rué; Xavier Xifró; Jian Xu; Zaira Ortega; José J Lucas; Paul J Lombroso; Jordi Alberch; Esther Pérez-Navarro
Journal:  J Neurosci       Date:  2011-06-01       Impact factor: 6.167

2.  Transgenic mice expressing caspase-6-derived N-terminal fragments of mutant huntingtin develop neurologic abnormalities with predominant cytoplasmic inclusion pathology composed largely of a smaller proteolytic derivative.

Authors:  Andrew T N Tebbenkamp; Cameron Green; Guilian Xu; Eileen M Denovan-Wright; Aaron C Rising; Susan E Fromholt; Hilda H Brown; Debbie Swing; Ronald J Mandel; Lino Tessarollo; David R Borchelt
Journal:  Hum Mol Genet       Date:  2011-04-22       Impact factor: 6.150

Review 3.  Epigenetics in nucleotide repeat expansion disorders.

Authors:  Fang He; Peter K Todd
Journal:  Semin Neurol       Date:  2012-01-21       Impact factor: 3.420

4.  Assessment of cortical and striatal involvement in 523 Huntington disease brains.

Authors:  Tiffany C Hadzi; Audrey E Hendricks; Jeanne C Latourelle; Kathryn L Lunetta; L Adrienne Cupples; Tammy Gillis; Jayalakshmi Srinidhi Mysore; James F Gusella; Marcy E MacDonald; Richard H Myers; Jean-Paul Vonsattel
Journal:  Neurology       Date:  2012-10-03       Impact factor: 9.910

5.  Increased 5-methylcytosine and decreased 5-hydroxymethylcytosine levels are associated with reduced striatal A2AR levels in Huntington's disease.

Authors:  Izaskun Villar-Menéndez; Marta Blanch; Shiraz Tyebji; Thais Pereira-Veiga; José Luis Albasanz; Mairena Martín; Isidre Ferrer; Esther Pérez-Navarro; Marta Barrachina
Journal:  Neuromolecular Med       Date:  2013-02-06       Impact factor: 3.843

Review 6.  Towards a better understanding of the cannabinoid-related orphan receptors GPR3, GPR6, and GPR12.

Authors:  Paula Morales; Israa Isawi; Patricia H Reggio
Journal:  Drug Metab Rev       Date:  2018-02-01       Impact factor: 4.518

7.  Gene expression profiling of brain samples from patients with Lewy body dementia.

Authors:  Maciej Pietrzak; Audrey Papp; Amanda Curtis; Samuel K Handelman; Maria Kataki; Douglas W Scharre; Grzegorz Rempala; Wolfgang Sadee
Journal:  Biochem Biophys Res Commun       Date:  2016-09-22       Impact factor: 3.575

Review 8.  Modulation of Molecular Chaperones in Huntington's Disease and Other Polyglutamine Disorders.

Authors:  Sara D Reis; Brígida R Pinho; Jorge M A Oliveira
Journal:  Mol Neurobiol       Date:  2016-09-22       Impact factor: 5.590

Review 9.  Neuronal Ca(2+) dyshomeostasis in Huntington disease.

Authors:  Marta Giacomello; Juan C Oliveros; Jose R Naranjo; Ernesto Carafoli
Journal:  Prion       Date:  2013-01-01       Impact factor: 3.931

10.  Genetic Deficiency of Complement Component 3 Does Not Alter Disease Progression in a Mouse Model of Huntington's Disease.

Authors:  Paul B Larkin; Paul J Muchowski
Journal:  J Huntingtons Dis       Date:  2012
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.